Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Cash from Financing Activities (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Cash from Financing Activities for 6 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities fell 64.86% to $1.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.7 million, a 58.26% decrease, with the full-year FY2024 number at $9.9 million, up 12.85% from a year prior.
  • Cash from Financing Activities was $1.5 million for Q3 2025 at Ensysce Biosciences, down from $1.9 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $9.2 million in Q4 2021 to a low of -$391270.0 in Q1 2022.
  • A 5-year average of $2.8 million and a median of $1.9 million in 2025 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: crashed 163.84% in 2022, then soared 4131.7% in 2024.
  • Ensysce Biosciences' Cash from Financing Activities stood at $9.2 million in 2021, then crashed by 78.88% to $1.9 million in 2022, then fell by 24.7% to $1.5 million in 2023, then plummeted by 92.3% to $112575.0 in 2024, then soared by 1189.33% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Cash from Financing Activities are $1.5 million (Q3 2025), $1.9 million (Q2 2025), and $1.3 million (Q1 2025).